ReviewExperimental and molecular pathology2009
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.
Review in Experimental and molecular pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05030519 (A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer), which is not on this map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer
Who cites it
60 citing papers in PubMed, 124 citations in OpenAlex.
- Article
- Climate change, environmental exposures, and breast cancer: advancing climate-resilient oncology through sustainable development goal 13.Frontiers in public health · 2026Review
- Phytochemicals in Breast Cancer Prevention and Treatment: A Comprehensive Review.Current issues in molecular biology · 2025Review
- Exploring lipidomic profiles and their correlation with hormone receptor and HER2 status in breast cancer.Oncology letters · 2025Article
- Design and Optimization of Trastuzumab-Functionalized Nanolipid Carriers for Targeted Capecitabine Delivery: Anti-Cancer Effectiveness Evaluation in MCF-7 and SKBR3 Cells.International journal of nanomedicine · 2025Article
- Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma.Scientific reports · 2024Article
- Energy-Efficient and Effective MCF-7 Cell Ablation and Electrothermal Therapy Enabled by M13-WSMaterials (Basel, Switzerland) · 2024Article
- Expression of c-erb-B2 oncoprotein as a neoantigen strategy to repurpose anti-neu antibody therapy in a model of melanoma.Research square · 2024Article
- Tumor characteristics and survival rate of HER2-low breast cancer patients: a retrospective cohort study.Scientific reports · 2023Article
- The Epigenetic Reader Methyl-CpG-Binding Protein 2 (MeCP2) Is an Emerging Oncogene in Cancer Biology.Cancers · 2023Review
- Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers.Pharmaceuticals (Basel, Switzerland) · 2022Article
- The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer.Military Medical Research · 2022Review
- The frequency and clinical significance of DNA polymerase beta (POLβ) expression in breast ductal carcinoma in situ (DCIS).Breast cancer research and treatment · 2021Article
- Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors.iScience · 2021Article
- Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach.International journal of molecular sciences · 2021Review
- CCA-1.1, a Novel Curcumin Analog, Exerts Cytotoxic anti- Migratory Activity toward TNBC and HER2-Enriched Breast Cancer Cells.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway.Molecular therapy : the journal of the American Society of Gene Therapy · 2021Article
- Heregulin-induced cell migration is prevented by trastuzumab and trastuzumab-emtansine in HER2+ breast cancer.Breast cancer research and treatment · 2021Article
- Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US.JAMA network open · 2021Article
- Breast tumor-on-chip models: From disease modeling to personalized drug screening.Journal of controlled release : official journal of the Controlled Release Society · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The HER2 gene encodes the receptor tyrosine kinase HER2 and is often over-expressed or amplified in breast cancer. Up-regulation of HER2 contributes to tumor progression. Many aspects of tumor growth are favorably affected through activation of HER2 signaling. Indeed, HER2 plays a role in increasing proliferation and survival of the primary tumor and distant lesions which upon completion of full transformation cause metastases. P185(HER2/neu) receptors and signaling from them and associated molecules increase motility of both intravasating and extravasating cells, decrease apoptosis, enhance signaling interactions with the microenvironment, regulate adhesion, as well as a multitude of other functions. Recent experimental and clinical evidence supports the view that the spread of incompletely transformed cells occurs at a very early stage in tumor progression. This review concerns the identification and characterization of HER2, the evolution of the metastasis model, and the more recent cancer stem cell model. In particular, we review the evidence for an emerging mechanism of HER2(+) breast cancer progression, whereby the untransformed HER2-expressing cell shows characteristics of stem/progenitor cell, metastasizes, and then completes its final transformation at the secondary site.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.